Short answer
Guardant Health, Inc. (GH) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $335M (up 44.3% year over year) with net income of −$120M.
Q2 2026 key financials · XBRL
- Revenue
- $335M
- +44.3% YoY · +11.0% QoQ
- Net income
- −$120M
- −20.3% YoY · −7.2% QoQ
- Operating margin
- -38.5%
- EPS (diluted)
- −$0.91
- −13.7% YoY · −7.1% QoQ
Source: XBRL data from the Guardant Health, Inc. (GH) Q2 2026 10-Q on SEC EDGAR. USD.
Guardant Health, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $335.0M, up 44% YoY from $232.1M
- Best segment Screening revenue $52.9M, up 257% YoY; volume approximately 66,000 vs 16,000
- Oncology revenue $219.1M, up 38% YoY; volume approximately 104,000 vs 64,000
- Net loss $120.1M vs $99.9M YoY; operating loss $129.1M vs $106.4M
- Cash, cash equivalents, and restricted cash approximately $1.2B as of June 30, 2026
Risk Factors
- No material changes to previously disclosed risk factors during Q2 fiscal 2026
- Carried-forward business risk: risks could materially adversely affect business, financial condition, cash flows, results, and stock price
- Carried-forward healthcare-industry risk: disclosed uncertainties may affect future operating results and financial condition
- Carried-forward forecasting risk: historical performance is not a reliable indicator of future performance
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Guardant Health, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.